ANNEX

to Decision No.
of the Council of the Eurasian Economic Commission
dated _____, 20___

AMENDMENTS
to the Rules for Marketing Authorization and Assessment of Medicinal Products for Human Use

1. Paragraph 17 shall be supplemented by the following indents:

"According to the results of amending the marketing authorization application of a medicinal product requiring re-authorization (authorization extension), when adding a new dosage form to the previously authorized one according to subparagraph "d", paragraph 2 of Addendum I to Annex No. 19 to the Rules, a marketing authorization with a new number shall be issued.

Marketing authorizations issued before May 22, 2022 shall be replaced with individual marketing authorization by the authorized body upon applicant's request and subject to payment of the relevant fee (duty) for issuance of the marketing authorization, if the condition contained in indent 2 of this paragraph is not met.".

2. Paragraph 187 shall read as follows:

"187. In specific cases, the medicinal product dosage form includes 3 types of additional products:

a) products included in the medicinal product package and not classified as medical devices;

b) products included in the medicinal product package, classified as medical devices and not intended for sale separately from such medicinal products;

c) products included in the medicinal product package, classified as medical devices, authorized as an independent medical device, which may be sold separately from the medicinal product.

3. It shall be supplemented with paragraph 187.[1] as follows:

"187.[1] Information on the products (including devices, component parts) included in the medicinal product package set and not classified as medical devices in accordance with the acts of the Union authorities in the field of medical devices circulation shall be included in the relevant sections of the medicinal product marketing authorization application in accordance with the requirements of Annex No. 1 to these Rules.

Products (including devices, component parts) included in the medicinal product package, classified as medical devices and not intended for sale separately from such medicinal products in the territory of the Union, are not subject to mandatory authorization in accordance with the Rules for Marketing Authorization and Expert Examination of Safety, Quality and Efficiency of Medical Devices approved by Decision No. 46 of the Eurasian Economic Commission's Council dated February 12, 2016 (hereinafter, the Rules for Marketing Authorization of Medical Devices) as medical devices. Information concerning these products (including devices, component parts) shall be submitted as part of the marketing authorization application of the medicinal product in accordance with the requirements of Annex No. 1 to these Rules during its marketing authorization procedure. In this case, the medicinal product marketing authorization covers all components of the dosage form. In this case, amendments to the medicinal product marketing authorization application concerning this product (including devices, component parts) shall be made in accordance with Section IX of these Rules.

Products (including devices, component parts) included in the medicinal product package set, classified as medical devices, and authorized as independent medical devices in accordance with the Rules for Marketing Authorization of Medical Devices or the legislation of the Member State as the medical devices, which may be sold separately from the medicinal products shall be accompanied by a copy of the marketing authorization of the medical device as part of the marketing authorization application, as well as information required by Annex No. 1 to these Rules, concerning these products. Amendments to the medicinal product marketing authorization application concerning the products (including devices, component parts) included in the package, including amendments relating to medical devices, shall be made in accordance with Section IX of these Rules.".

4. In Annex No. 1 to these Rules:

a) in paragraph 1.3, replace the word "labeling" with the phrase "package layouts with labeling";

b) in paragraph 1.3.2 replace the phrase "and labeling" with the phrase "with labeling", add the phrase "(hereinafter, the package layouts)" after the phrase "by the Commission";

c) in the seventh indent of paragraph 15.2, delete the word "labeling".

d) the sixth indent of paragraph 3.2.P.1 shall read as follows:

"This information shall be supplemented by any relevant data concerning the container (primary package) type and its sealing method (if applicable), as well as a summary of the products (including devices and component parts) using which the medicinal product is to be used or administered and which are to be supplied together with the medicinal product."

e) in paragraph 3.2.P.2:

in the tenth indent, add the word "(sealing)" after the words "primary package";

add indents with the following wording:

"If the medicinal product primary package is a device using which the medicinal product is to be used or administered (hereinafter, the Administration Device) or if the package set includes products (including devices, component parts), this section of the marketing authorization application shall contain information justifying their choice.

The intended use of a particular device, component part, including medical device, functionality, suitability for use in the context of the medicinal product, therapeutic indication for its use, administration method and dosing regimen in the target patient population shall be considered.

Functional aspects of a particular device, component part, including the medical device, shall be assessed in terms of the choice justification (e.g. dose delivery characteristic and physical functionality of the device, component part, medical device).

A summary of the packaging (closure) system of the medicinal product, its component device, component parts, medical device, if applicable, shall be provided, for example:

justification for the use of additional package;

description of the device critical functional part (e.g., the mechanism that administers and/or regulates the medicinal product dose);

description of features increasing safety of the medicinal product for a user with respect to the dose delivery (e.g. possibility to hear clearly the click of the dosing and/or administration device);

description of the features preventing a user from cutting and stabbing injuries;

presence of safeguards preventing the medicinal product overdose;

indication of information on safe disposal, etc.;

indication of information on medicinal product releasing carrier or reservoir (including mechanism of release of such medicinal product, etc.) for medicinal products with implantable or transdermal route of administration.

The characterization of functional aspects shall be limited to only those functional aspects that affect the safety, efficacy and quality of the medicinal product (and thus the final benefit/risk ratio). Such characteristics include, but are not limited to, the correctness and accuracy of the measured dose within the range of use (reuse) of the device, physical functionality and/or other aspects directly related to the intended use of the device. Specifically, the ability to deliver and/or administer the medicinal product in accordance with the dosing regimen specified in Section 4.2 of its SmPC in a correct and reproducible manner shall be demonstrated.

If the medicinal product primary package is a device or the medicinal product package components are classified as medical devices, it is necessary to provide data on compatibility between materials of the package components in contact with the medicinal product, including compatibility with any solvents for reconstitution of this medicinal product and/or data on the effect of the package components on quality attributes of this medicinal product. Studies shall demonstrate that there is no impact on the safety, efficacy and quality of the medicinal product. The following aspects (if applicable) shall be considered:

the material compatibility of the package components with the medicinal product shall be considered in terms of ensuring the required chemical and physical stability of the medicinal product (e.g. sorption, precipitation of the medicinal product active ingredient in solution, medicinal product stability, package extractables and leachables and other aspects based on the specific type of the package and medicinal product). Material

interaction studies of the package components coming in contact with the medicinal product can be conducted using the risk-based and time-of-contact approach or during medicinal product transportation simulating studies;

studies of the medicinal product interaction with process additives (e.g. lubricants, glue and/or adhesive label materials) used at processing of parts of the primary packaging (closure) system component (including devices, component parts, medical devices) of the medicinal product and come into direct contact with this medicinal product.

The relevant sections of modules 2, 4 and 5 of the marketing authorization application shall contain information on clinical evidence of safety and efficacy of the primary packaging (closure) system, component part, medical device used co-use with the medicinal product.

e) in paragraph 3.2.P.3:

supplement subparagraph "a" with the following indent:

"If the medicinal product primary package is a device, the manufacturing sites for the medicinal product integration with the device, if applicable, the sites for packaging, sterilization, labeling, and quality control shall be listed in addition to the name, address, and responsibilities of each manufacturer of the medicinal product."

supplement by subparagraph "d" with the following wording:

"d) if the medicinal product primary package is an administration device, the sterilization procedure data (if applicable), including information on the sterilization process validation and data on the primary packaging process validation (for sterile device parts (if applicable)), shall be provided.

A description of the medicinal product manufacturing process in such a case shall include operations related to the medicinal product integration into the device. Critical processes, techniques and/or packaging operations that directly affect the quality of the entire product shall be described in detail.

The following information shall be included in the description of the manufacturing process:

an appropriate description of any manufacturing steps performed by the medicinal product manufacturer to prepare the device for its final integration with the medicinal product (e.g., subassembly, washing, coating, sterilization, depyrogenation steps);

a description of sterilization methods and conditions. Information on the individual sterilization process of the device shall be also provided in the specified section of the marketing authorization application (if applicable).

If the medicinal product primary package is a device, names and addresses of the manufacturing sites for the medicinal product integration with the device and, if applicable, the sites for packaging, sterilization, labeling and quality control of the device shall be specified in addition to the name, address and responsibilities of each manufacturer of the medicinal product.

If the medicinal product package set includes products (including devices, component parts) which are not intended to be sold separately from the medicinal product, the production sites producing these products and their production process flow-chart (if applicable) shall be specified in addition to the name, address and responsibilities of each manufacturer of the medicinal product.";

g) supplement paragraph 3.2.P.5 by the following indents:

"If the medicinal product primary package is an administration device, the medicinal product specification may contain functional test data applicable to the administration device (e.g., extractable volume, dosing consistency, piercing force, etc.).

If the medicinal product package set includes a ready-to-use sterile component part or medical device, information confirming its sterility shall be provided.";

h) paragraph 3.2.P.7 shall be read as follows:

"3.2.P.7. Packaging (closure) system.

A description of the primary (internal) package and closure system, including materials of which each primary package component is made, as well as specifications for these materials shall be provided. The specifications shall include the materials description and identification. Non-pharmacopoeial analytical methods (including analytical procedure validation) shall be submitted where appropriate.

If the medicinal product primary package is an administration device, a description of the administration device including the materials of which each administration device component coming into contact with the medicinal product is made and the specifications of those materials, shall be provided.

Material specifications shall include a description and identification of the primary packaging materials. Information of non-pharmacopoeial analytical procedures/methods (including analytical procedure validation) shall be submitted where appropriate.

For non-functional device components, materials of the medicinal product secondary (consumer) and intermediate package, their brief description only shall be provided. For functional components of the secondary (consumer) and intermediate package, devices, component parts and medical devices included in the medicinal product package set, additional information on functional properties shall be provided.

If the medicinal product primary package is a device, specifications (including a description, identification and functional tests of the device, if applicable) and critical dimensions (with diagrams and photographs where

applicable) shall be provided. Specifications shall reflect the device functional and process features in such a way that equivalence between devices from different suppliers can be guaranteed. Analytical procedures for assessing the functional and process features of the device shall be provided, if required.

If the medicinal product package set includes a component part, including a medical device, the corresponding section of the marketing authorization application shall contain their summary. Where applicable, the specification used by the medicinal product manufacturer for acceptance control shall be provided.";

i) supplement paragraph 3.2.P.8 with subparagraph "d" with the following wording:

"d) if the medicinal product primary package is an administration device, medicinal product stability studies shall include, but not limited to, the following:

functional tests identified as critical parameters for the medicinal product quality;

tests of critical parameters indicating the medicinal product stability (e.g. microbiological purity, sterility, device integrity, content (potency) and purity) during the shelf life and ready-to-use period (if applicable). If necessary, appropriate and scientifically valid alternatives to sterility tests (e.g., device integrity test) may be used.

If the medicinal product package set includes a component part, medical device, the following shall be submitted:

data on the medicinal product stability when in contact with the component, medical device for the period of its use;

the component part, medical device functionality parameters affecting the medicinal product safety, efficacy and quality (and thus the final benefit-risk ratio).";

k) add paragraph 3.2.R.1 to read as follows:

"3.2.R.1 Medical devices or products (including devices, component parts).

If the medicinal product package set includes medical device or products (including devices, component parts), the following information confirming their official status shall be submitted in this section of the marketing authorization application, whichever is applicable:

information on the medical device authorization in accordance with the Rules for Marketing Authorization and Expert Examination of Safety, Quality and Efficiency of Medical Devices approved by Decision No. 46 of the Eurasian Economic Commission's Council dated February 12, 2016 or the legislation of the Member State (if applicable);

a copy of the authorization giving the right to manufacturing in the country of the manufacturer with an annex thereto (if any)

a copy of the certificate of the quality management system conformity to the requirements of the ISO 13485 standard or the corresponding regional or national/state standard of the Member State of the Eurasian Economic Union, issued in the name of the medical device manufacturer (production site) (if any)

a declaration of conformity of the medical device to the mandatory requirements of the third countries (for example, directives or regulations of the European Union), or an equivalent document (if any) or copies of such documents;

for medical devices with the CE mark or special mark of medical devices circulation on the Union market, the manufacturer's declaration of

conformity of the medical device to the European or Union standards (if available) shall be submitted;

a copy of the marketing authorization of the medical device (free sale certificate, export certificate) issued in the country of the manufacturer of the medical device or medicinal product, or in the Member State in accordance with the legislation of the country of the manufacturer or the Member State (if any);

information on marketing authorization in the third countries with reference to the current sources of such information and an electronic file containing such information, or a copy of the document certifying the medical device marketing authorization in the third countries (if any).

In addition, this section shall include:

information on special software (in case of absence of information in the SmPC and Prescribing Information of the medicinal product) (if applicable);

an operation document or Prescribing Information in Russian and in state languages of Member States (if this information is not included in the SmPC and Prescribing Information the medicinal product) (if applicable);

service manual (if there is no information on such service in the SmPC and Prescribing Information of the medicinal product) (if applicable)".

5. In Annex No. 2 to these Rules:

a) in Section I, subsection 2, replace phrase "in labeling" with the phrase "on secondary package";

b) in Section II, paragraph 3.5.1, replace the phrase "in labeling" with the phrase "on the secondary package";

c) in Section III, paragraph 3.5.1, replace the phrase "in labeling" with the phrase "on the secondary package";

6. In Annex No. 4 to these Rules, Section I, paragraph 1.3, replace the word "labeling" with the phrase "package layouts".

7. Paragraphs 3 and 4, Section VI, Annex No. 11 to these Rules shall read as follows;

"3. Possibility to approve package layouts.

4. Possibility to approve the Prescribing Information (Package Information Leaflet) of a medicinal product (PI (drug substance)).".

8. In Section II, Annex No. 14 to these Rules:

a) the second sentence of the ninth indent shall read as follows:

"Issues arising from the scientific evaluation below and related to the drug product information (comments on the SmPC, Prescribing Information (Package Information Leaflet), medicinal product package layouts) shall be mentioned as well.

b) in the title of subsection 7, replace the word "labeling" with the phrase "package layouts";

c) in the fourth indent of subsection 9, replace the word "labeling" with the phrase "package layouts".

9. In the third indent of paragraph 7.1 of Annex No. 15 to these Rules, replace the word "labeling" with the phrase "package layouts".

10. In paragraph V.4, replace the word "Labeling" with the phrase "Package Layouts".

11. In Annex No. 18 to these Rules:

a) in paragraph 2.1, replace the word "labeling" with the phrase "package layouts";

b) in paragraph 3.1, replace the word "labeling" with the phrase "package layouts".

12. In Annex No. 19 to these Rules:

a) in the seventh indent of paragraph 1.2, in paragraph 1.6.1 and in the fourth indent of paragraph 2.4.1, replace the word "labeling" with the phrase "package layouts";

b) in Addendum III:

in paragraph 4, replace the phrase "of the labeling or Package Information Leaflet" with the phrase "Package Information Leaflet or package layouts";

in paragraph 10, replace the word "labeling" with the phrase "package layouts";

c) in Addendum V:

in the twenty-second indent, delete the word "labeling" and replace the word "packages" with the phrase "of the packages";

in paragraph B.II.e.6, replace the phrase "change of the labeling design, color" with the phrase "change of the intermediate or secondary package layout design/color";

in paragraph B.I.1:

replace the word "labeling" with the phrase "package layouts";

in the Conditions Section:

in subparagraph 1, replace the word "labeling" with the phrase "package layouts";

in subparagraph 2, replace the word "labeling" with the phrase "package layouts";

in paragraphs B.I.2, B.I.3 and B.I.4, replace the word "labeling" with the phrase "package layouts";

in paragraph B.I.13, replace the word "labeling" with the phrase "package layouts" (twice).

d) in Addendum VI:

in paragraph B.II.e.6, replace the phrase "change of the labeling design, color" with the phrase "change of the intermediate or secondary package layout design/color";

in paragraph B.I.1:

replace the word "labeling" with the phrase "package layouts";

in the Conditions Section:

in subparagraph 1, replace the word "labeling" with the phrase "package layouts";

in subparagraph 2, replace the word "labeling" with the phrase "package layouts";

in paragraphs B.I.2 and B.I.3, replace the word "labeling" with the phrase "package layouts";

13. In Annex No. 21 to these Rules:

a) in the fourth indent of paragraph 4.1, replace the word "labeling" with the phrase "package layouts";

b) in the title of Annex A, replace the word "labeling" with the phrase "package layouts".

14. In Annex No. 24 to these Rules:

a) in paragraph 1.3, subsection 5.2 and paragraph 1.3, subsection 5.4, replace the word "labeling" with the phrase "package layouts";

b) in paragraph 1.3.1, subsection 5.2 and paragraph 1.3.1, subsection 5.4, replace the word "labeling" with the phrase "packages".

15. In the third indent of subsection 1, Section V of Annex No. 26 to these Rules, replace the word "labeling" with the phrase "package layouts".

_____